A randomized phase III trial showed that neoadjuvant chemotherapy did not improve disease-free survival (DFS) over upfront surgery in patients with locally advanced colon cancer. The study included 248 patients. Among patients, DFS rates were similar when comparing both strategies. Neoadjuvant chemotherapy was administered before surgery. Upfront surgery meant surgery immediately without prior chemotherapy. The study did not show superiority of one strategy over another in DFS.[1][2]